HIGHLIGHTS
- who: Top from the Unit of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy IRCCS AOU San Martino IST and University of Genoa, Genova, Italy have published the paper: cohort study, in the Journal: (JOURNAL)
- what: The authors aimed to identify clinical predictors of long-term response to abiraterone (defined as >12 months drug exposure) in a retrospective cohort of metastatic castration-resistant prostate cancer patients treated in post-docetaxel setting at 24 Italian centers. The main reasons for treatment failure before starting abiraterone included PSA progression (33%) both PSA andradiological progression (55%) and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.